Clinical Trial Update: Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of Zanubrutinib, Rituximab, Lenalidomide (ZR²) in combination with Tislelizumab for relapsed/refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (Revlimid) (lenalidomide)
• Rituximab (Rituxan) (rituximab)
• Tislelizumab (Tuoyi) (tislelizumab)
• Zanubrutinib (Brukinsa) (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Relapsed/Refractory Follicular Lymphoma | Phase 2 | Status: RECRUITING